INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH CHOROIDAL NEVUS

被引:15
作者
Chiang, Allen [2 ]
Bianciotto, Carlos [1 ]
Maguire, Joseph I. [2 ]
Park, Carl H. [2 ]
Baker, Paul S. [2 ]
Shields, Jerry A. [1 ]
Shields, Carol L. [1 ]
机构
[1] Thomas Jefferson Univ, Wills Eye Inst, Ocular Oncol Serv, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Wills Eye Inst, Retina Serv, Philadelphia, PA 19107 USA
来源
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES | 2012年 / 32卷 / 01期
关键词
choroid; nevus; choroidal neovascularization; hemorrhage; bevacizumab; avastin; 3422 CONSECUTIVE EYES; PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; SECONDARY; AGE; GROWTH; VERTEPORFIN; MELANOMAS; AVASTIN; TUMORS;
D O I
10.1097/IAE.0b013e31822092b7
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To report 10 cases of occult choroidal neovascularization (CNV) associated with choroidal nevus managed with intravitreal bevacizumab. Methods: Interventional case series. Each nevus was examined and imaged with fluorescein angiography, B-scan ultrasonography, and optical coherence tomography. Data were retrospectively analyzed to evaluate outcomes of treatment response and visual acuity. Results: Nine patients presented with CNV overlying a chronic choroidal nevus with a posterior margin within 1.5 mm of the foveola. In the 10th patient, the posterior margin of the nevus was located 10 mm from the foveola with extension of subretinal fluid into the macula. The CNV was subfoveolar in four cases, juxtafoveolar in two cases, and extrafoveolar in four cases. Initial visual acuity was 20/20 to 20/50 in 5, 20/60 to 20/100 in 2, and 20/200 or worse in 3 cases. Clinical features included subfoveolar fluid in nine, exudation in five, and hemorrhage in four cases. Intravitreal bevacizumab (1.25 mg/0.05 cc) was injected with regression of CNV in all 10 cases using 2 to 14 injections (median 3 injections). In 2 eyes, after therapeutic response to bevacizumab later consolidation with photodynamic therapy (juxtafoveolar CNV) (n = 1) or conventional laser (extrafoveolar CNV) (n = 1) was provided. In the remaining 8 eyes, after discontinuation of bevacizumab, there was no recurrence of CNV over mean 10.1 months. At overall mean follow-up of 22.5 months, final visual acuity decreased by 1 line in 4 cases and improved by mean of 3 lines (range, 1-8 lines) in 6 cases. There were no adverse effects from bevacizumab injections. All 10 choroidal nevi remained stable. Conclusion: Intravitreal bevacizumab appears to be an effective treatment option for CNV secondary to choroidal nevus. In some cases, depending on the proximity of the CNV to the foveola, photodynamic therapy or conventional laser may be useful adjunctive therapy. RETINA 32:60-67, 2012
引用
收藏
页码:60 / 67
页数:8
相关论文
共 28 条
[1]  
Arnold J, 2001, OPHTHALMOLOGY, V108, P841
[2]   Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration [J].
Avery, RL ;
Pieramici, DJ ;
Rabena, MD ;
Castellarin, AA ;
Nasir, MA ;
Giust, MJ .
OPHTHALMOLOGY, 2006, 113 (03) :363-372
[3]  
Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
[4]  
BUTLER P, 1994, OPHTHALMOLOGY, V101, P710
[5]  
Byrne SF, 1983, OPHTHALMIC ULTRASONO, P149
[6]   CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH CHOROIDAL NEVI [J].
CALLANAN, DG ;
LEWIS, ML ;
BYRNE, SF ;
GASS, JDM .
ARCHIVES OF OPHTHALMOLOGY, 1993, 111 (06) :789-794
[7]   Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin [J].
Chan, Wai-Man ;
Lai, Timothy Y. Y. ;
Liu, David T. L. ;
Lam, Dennis S. C. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2007, 143 (06) :977-983
[8]   Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration [J].
Chang, Louis K. ;
Spaide, Richard F. ;
Brue, Claudia ;
Freund, K. Bailey ;
Klancnik, James M., Jr. ;
Slakter, Jason S. .
ARCHIVES OF OPHTHALMOLOGY, 2008, 126 (07) :941-945
[9]  
FOLK JC, 1989, OPHTHALMOLOGY, V96, P547
[10]  
GASS JDM, 1980, OPHTHALMOLOGY, V87, P523